Join
Live feed
·
PRReleasevia Quantisnow
BridgeBio Pharma Inc. logo

BridgeBio Pharma and Affiliate QED Therapeutics Announce FDA Acceptance of New Drug Application for Infigratinib for the Treatment of Cholangiocarcinoma

ByQuantisnow·Wall Street's wire, on your screen.
BBIO· BridgeBio Pharma Inc.
Health Care
Original source

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track BBIO (BridgeBio Pharma Inc.) and more on Quantisnow.